1221412-23-2
Chemical Structure
IMM-H007
Synonym(s): WS070117
- CAS No.: 1221412-23-2
- Formula:C22H23N5O8
- Molecular Weight:485.45
IUPAC Name: (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-((3-hydroxyphenyl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate
InChIKey: IUDLPZTURGVXEA-WGQQHEPDSA-N
SMILES: CC(O[C@H]1[C@@](N2C3=NC=NC(NC4=CC(O)=CC=C4)=C3N=C2)([H])O[C@@H]([C@H]1OC(C)=O)COC(C)=O)=O
Biological Activity: IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IMM-H007 | 97.69% | IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yu J, et al. IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732. [Content Brief]
- [2]. Shi H, et al. IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet. FEBS Open Bio. 2017 Aug 29;7(9):1379-1391. [Content Brief]
- [3]. Wang SX, et al. IMM-H007 attenuates isoprenaline-induced cardiac fibrosis through targeting TGFβ1 signaling pathway. Acta Pharmacol Sin. 2022 Mar 30. [Content Brief]
